SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 26.03 |
| Enterprise Value ($M) | -30.49 |
| Book Value ($M) | 22.97 |
| Book Value / Share | 0.40 |
| Price / Book | 1.13 |
| NCAV ($M) | 21.30 |
| NCAV / Share | 0.37 |
| Price / NCAV | 1.22 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -3.38 |
| Return on Assets (ROA) | -0.68 |
| Return on Equity (ROE) | -1.16 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.11 |
| Current Ratio | 3.11 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 60.57 |
| Assets | 62.24 |
| Liabilities | 39.27 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted Distributed | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Highbridge Capital Management Llc | |||
| 13G/A | Short Jay M Phd | |||
| 13G/A | Millennium Management Llc | |||
| 13G/A | Tang Capital Management Llc | 1.80 | ||
| 13D/A | Soleus Private Equity Fund I, L.P. | 2.56 | -53.26 | |
| 13G/A | BlackRock, Inc. | 1.60 | -72.55 | |
| 13G/A | Tang Capital Partners Lp | 5.30 | -19.21 | |
| 13G/A | Acorn Bioventures, L.p. | 8.40 | 47.89 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 235,690 | 873,519 | 26.98 | |
| 82,373 | 328,466 | 25.08 | |
| 185,423 | 530,826 | 34.93 | |
| 239,307 | 999,741 | 23.94 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| AVDL – Avadel Pharmaceuticals plc | AVTE – Aerovate Therapeutics, Inc. |
| AXSM – Axsome Therapeutics, Inc. | BHST – BioHarvest Sciences Inc. |
| BTMD – biote Corp. |
Financial data and stock pages provided by
Fintel.io